Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/rmv.2143 http://scihub22266oqcxt.onion/10.1002/rmv.2143 32779326!7435512!32779326     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Rev+Med+Virol 2020 ; 30 (6): 1-10 Nephropedia Template TP {{tp|p=32779326|t=2020. Drugs against SARS-CoV-2: What do we know about their mode of action?|pdf=|usr=}}{{32779326}} gab.com Text Drugs against SARS-CoV-2: What do we know about their mode of action JO: Rev Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=32779326 #FOAvip The health emergency caused by the recent Covid-19 pandemic highlights the need to identify effective treatments against the virus causing this disease (SARS-CoV-2). The first clinical trials have been testing repurposed drugs that show promising anti-SARS-CoV-2 effects in cultured cells. Although more than 2400 clinical trials are already under way, the actual number of tested compounds is still limited to approximately 20, alone or in combination. In addition, knowledge on their mode of action (MoA) is currently insufficient. Their first results reveal some inconsistencies and contradictory results and suggest that cohort size and quality of the control arm are two key issues for obtaining rigorous and conclusive results. Moreover, the observed discrepancies might also result from differences in the clinical inclusion criteria, including the possibility of early treatment that may be essential for therapy efficacy in patients with Covid-19. Importantly, efforts should also be made to test new compounds with a documented MoA against SARS-CoV-2 in clinical trials. Successful treatment will probably be based on multitherapies with antiviral compounds that target different steps of the virus life cycle. Moreover, a multidisciplinary approach that combines artificial intelligence, compound docking, and robust in vitro and in vivo assays will accelerate the development of new antiviral molecules. Finally, large retrospective studies on hospitalized patients are needed to evaluate the different treatments with robust statistical tools and to identify the best treatment for each Covid-19 stage. This review describes different candidate antiviral strategies for Covid-19, by focusing on their mechanism of action. Twit Text FOAVip Drugs against SARS-CoV-2: What do we know about their mode of action ????Rev Med Virol http://www.kidney.de/pget.php?&tw=1&pmid=32779326 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32779326 #FOAvip English Wikipedia <ref>{{Cite pmid|32779326}}</ref> Drugs against SARS-CoV-2: What do we know about their mode of action? #MMPMID32779326 Valle C; Martin B; Touret F; Shannon A; Canard B; Guillemot JC; Coutard B; Decroly E Rev Med Virol 2020[Nov]; 30 (6): 1-10 PMID32779326show ga The health emergency caused by the recent Covid-19 pandemic highlights the need to identify effective treatments against the virus causing this disease (SARS-CoV-2). The first clinical trials have been testing repurposed drugs that show promising anti-SARS-CoV-2 effects in cultured cells. Although more than 2400 clinical trials are already under way, the actual number of tested compounds is still limited to approximately 20, alone or in combination. In addition, knowledge on their mode of action (MoA) is currently insufficient. Their first results reveal some inconsistencies and contradictory results and suggest that cohort size and quality of the control arm are two key issues for obtaining rigorous and conclusive results. Moreover, the observed discrepancies might also result from differences in the clinical inclusion criteria, including the possibility of early treatment that may be essential for therapy efficacy in patients with Covid-19. Importantly, efforts should also be made to test new compounds with a documented MoA against SARS-CoV-2 in clinical trials. Successful treatment will probably be based on multitherapies with antiviral compounds that target different steps of the virus life cycle. Moreover, a multidisciplinary approach that combines artificial intelligence, compound docking, and robust in vitro and in vivo assays will accelerate the development of new antiviral molecules. Finally, large retrospective studies on hospitalized patients are needed to evaluate the different treatments with robust statistical tools and to identify the best treatment for each Covid-19 stage. This review describes different candidate antiviral strategies for Covid-19, by focusing on their mechanism of action. |*COVID-19 Drug Treatment[MESH] |Antiviral Agents/*pharmacology/*therapeutic use[MESH] |COVID-19/*virology[MESH] |Combined Modality Therapy[MESH] |Disease Management[MESH] |Disease Susceptibility[MESH] |Drug Development[MESH] |Drug Repositioning[MESH] |Host-Pathogen Interactions[MESH] |Humans[MESH] |SARS-CoV-2/*drug effects/*physiology[MESH]Drugs against SARS-CoV-2: What do we know about their mode of action?(epmc).pdf DeepDyve Pubget Overpricing